Hall Criteria for Down Syndrome Screening
I need to clarify an important point: The evidence provided does not contain any reference to "Hall criteria" for Down syndrome screening. The term "Hall criteria" does not appear in any of the guideline or research documents reviewed.
What the Current Guidelines Actually Recommend
The most recent and authoritative guidance comes from the 2025 ACMG Technical Standard, which recommends cell-free DNA (cfDNA) screening as the primary screening method for Down syndrome in the general population, replacing traditional biochemical and ultrasound-based approaches 1.
Modern Screening Approaches (2025 Guidelines)
The current state-of-the-art screening strategies include:
Primary cfDNA Screening (Preferred)
- Sensitivity and specificity >99% for Down syndrome 1
- Can be offered as first-line screening to all pregnant women
- Very low false-positive rate
- Reveals fetal sex early in pregnancy
Combined First-Trimester Screening (Alternative)
When cfDNA is not available or chosen, the combined test includes 2, 1:
Required Components:
- Maternal age
- Nuchal translucency (NT) measurement by ultrasound (11-13 weeks)
- Pregnancy-associated plasma protein A (PAPP-A)
- Free β-hCG or total hCG
Performance:
- Detection rate: 82-86% at 5% false-positive rate
- Free β-hCG performs 2-3% better than total hCG at 11 weeks 2
Integrated/Contingent Screening Models
Two validated approaches merge first-trimester screening with cfDNA 1:
- Contingent Model: First-trimester results stratified into high-risk, moderate-risk, and low-risk groups; moderate-risk patients offered cfDNA
- Reflex Model: Automatic cfDNA testing for positive first-trimester screens
Both achieve 91-95% detection rates for common trisomies 1.
Critical Technical Requirements
For NT Measurement 2:
- Must be performed by experienced, credentialed sonographer
- Measurement in millimeters at 11-13 weeks gestation
- Crown-rump length (CRL) must be documented
- Sonographer identification required on report
For Biochemical Testing 2:
- Results reported in both mass units (ng/mL) and multiples of median (MoM)
- Adjustments for maternal weight, race, diabetes, and gestational age
- Laboratory must participate in external proficiency testing
What You May Be Looking For
If you're asking about clinical features of Down syndrome (rather than screening criteria), the guidelines describe 2:
Physical Features:
- Hypotonia (virtually all individuals)
- Upslanting palpebral fissures
- Epicanthal folds
- Flat nasal bridge
- Brushfield spots of iris
- Shortened, incurving fifth finger
- Transverse palmar crease
Associated Conditions:
- Congenital heart disease (40% of cases)
- Gastrointestinal anomalies (5%): duodenal atresia, Hirschsprung disease
- Increased childhood leukemia risk (20-fold)
- Alzheimer-type neurodegeneration in adults
Common Pitfall
The term "Hall criteria" does not exist in current Down syndrome screening guidelines. You may be confusing this with other medical criteria systems, or this may be outdated terminology. The current standard is the ACMG 2025 Technical Standard for prenatal screening, which emphasizes cfDNA as primary screening with combined first-trimester biochemical/ultrasound screening as an alternative 1.